Results 51 to 60 of about 1,016,262 (299)
The effects of Parkinson's disease mimetics on the proteasomal and neurofilament systems in SH-SY5Y cells [PDF]
, 2006 Mitochondrial impairment, glutathione depletion and oxidative stress have been implicated in the pathogenesis of Parkinson's disease, linked recently to proteasomal dysfunction.
Caneda-Ferrón, B +1 more
core
, 2017 Key Points Proteasome inhibition activates multiple kinases in myeloma cells resulting in the phosphorylation of p53, HSP27, c-JUN, and HSF1.
Lawrence H. Boise +3 more
core +1 more source
Elucidating Proteasome Catalytic Subunit Composition and Its Role in Proteasome Inhibitor Resistance [PDF]
, 2016 Proteasome inhibitors bortezomib and carfilzomib are FDA-approved anticancer agents that have contributed to significant improvements in treatment outcomes. However, the eventual onset of acquired resistance continues to limit their clinical utility, yet
Carmony, Kimberly C.
core +1 more source
Proteasome inhibition enhances lysosome-mediated targeted protein degradation
Cell Death and DiseaseProteasome inhibitor drugs are currently used in the clinic to treat multiple myeloma and mantle cell lymphoma. These inhibitors cause accumulation of undegraded proteins, thus inducing proteotoxic stress and consequent cell death.
Ahmed M. Elshazly +9 more
doaj +1 more source
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival
Molecular Oncology, EarlyView.CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna +8 more
wiley +1 more source
Molecular Oncology, EarlyView.Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis +20 more
wiley +1 more source
SylC Catalyzes Ureido-Bond Formation During Biosynthesis of the Proteasome Inhibitor Syringolin A
, 2016 SylC Catalyzes Ureido-Bond Formation During Biosynthesis of the Proteasome Inhibitor Syringolin
Heidi J. Imker (2031736) +2 more
core +1 more source
The proteasome cap RPT5/Rpt5p subunit prevents aggregation of unfolded ricin A chain [PDF]
, 2013 The plant cytotoxin ricin enters mammalian cells by receptor-mediated endocytosis, undergoing retrograde transport to the endoplasmic reticulum (ER) where its catalytic A chain (RTA) is reductively separated from the holotoxin to enter the cytosol and ...
Spooner, Robert A. +12 more
core +1 more source
Proteasome inhibitors for multiple myeloma [PDF]
Japanese Journal of Clinical Oncology, 2018 Therapeutic strategies for multiple myeloma have dramatically changed in the last two decades, especially after the introduction of proteasome inhibitors. The first-in-class proteasome inhibitor, bortezomib, was approved by the US Food and Drug Administration in 2003.
Kiyoshi, Okazuka, Tadao, Ishida
openaire +2 more sources
Identification of a peptoid inhibitor of the proteasome 19S regulatory particle
, 2016 The first chemical inhibitor of the 19S regulatory particle (RP) of the proteasome is described. The molecule was identified by screening a library of nucleoside-capped peptoids for binding to the yeast 26S proteasome in a crude extract.
Kodadek, T +5 more
core +2 more sources